Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPS: Immunomodulatory Treatment of Surfactant-Related Interstitial Lung Disease
2026-525336-41-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of prednisone, prednisolone, azithromycin and hydroxychloroquine in interstitial lung disease (ILD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Forced vital capacity decline at one year. Planned start Aug 2026; status: authorised.
02
Drugs
prednisoneprednisoloneazithromycinhydroxychloroquine
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2026-525336-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525336-41-00.